EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

Factors associated with primary rifampicin-resistant/multidrug-resistant TB: a case-control study

T Zangpo, T Norbu, P Tenzin, G Nima, C Dorji, G P Dhakal, S Dorjee, T Tsheten

The International Journal of Tuberculosis and Lung Disease · 2026

DOI: 10.5588/ijtld.26.0038 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2026. Verfasst von T Zangpo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gidakom Hospital, National Medical Services, Ministry of Health, Thimphu, Bhutan. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Rifampin, Antitubercular Agents, Tuberculosis, Pulmonary.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

Multidrug-resistant TB (MDR-TB) threatens TB control in Bhutan. According to the 2017 national Drug Resistance Surveillance report of the Royal Centre for Disease Control, 13.7% of new pulmonary TB cases had rifampicin resistance, of whom 98% were also resistant to isoniazid. We investigated the factors associated with primary rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB) among new pulmonary TB patients.





METHODS

We conducted a nationwide case-control study including 46 laboratory-confirmed primary RR/MDR-TB cases and 138 drug-susceptible pulmonary TB controls (1:3 ratio). Multivariable logistic regression identified factors independently associated with primary RR/MDR-TB.





RESULTS

Factors associated with primary RR/MDR-TB were delay in diagnosis (adjusted odds ratio [AOR] 24.9, P < 0.001), poor household ventilation (AOR 3.6, P = 0.023), contact with MDR-TB patients (AOR 7.2, P < 0.001), living alone (AOR 10.8, P = 0.016), perceived health staff unfriendliness (AOR 9.6, P = 0.004), and TB medicine unavailability (AOR 16.5, P = 0.024). Increasing age was associated with lower odds of RR/MDR-TB (AOR 0.94 per year, P = 0.005).





CONCLUSION

Primary RR/MDR-TB in Bhutan was strongly associated with delayed diagnosis, contact with known MDR-TB patients and modifiable health-system factors. Expanding rapid molecular testing, strengthening contact investigation, and improving patient-centred care are critical to interrupt transmission and sustain TB control gains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantRifampinAntitubercular AgentsTuberculosis, PulmonaryHumansCase-Control StudiesMaleFemaleAdultMiddle AgedRisk FactorsYoung AdultAdolescentLogistic ModelsMycobacterium tuberculosisIsoniazidDelayed Diagnosis

Substanzen

RifampinAntitubercular AgentsIsoniazid

Autor:innen und Institutionen

  • Gidakom Hospital, National Medical Services, Ministry of Health, Thimphu, Bhutan.
  • Medical Education Centre for Research, Innovation and Training, Khesar Gyalpo University of Medical Sciences of Bhutan, Thimphu, Bhutan.
  • National TB Control Program, Department of Public Health, Ministry of Health, Thimphu, Bhutan.
  • Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Jigme Dorji Wangchuk National Referral Hospital, Thimphu, Bhutan.
  • Khesar Gyalpo University of Health Sciences of Bhutan, Thimphu, Bhutan.

Zitieren

APA

Zangpo, T., Norbu, T., Tenzin, P., Nima, G., Dorji, C., Dhakal, G. P., Dorjee, S., & Tsheten, T. (2026). Factors associated with primary rifampicin-resistant/multidrug-resistant TB: a case-control study. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.26.0038

Vancouver

Zangpo T, Norbu T, Tenzin P, Nima G, Dorji C, Dhakal GP, et al. Factors associated with primary rifampicin-resistant/multidrug-resistant TB: a case-control study. The International Journal of Tuberculosis and Lung Disease. 2026. doi:10.5588/ijtld.26.0038

BibTeX
@article{Zangpo2026,
  author = {Zangpo, T and Norbu, T and Tenzin, P and Nima, G and Dorji, C and Dhakal, G P and Dorjee, S and Tsheten, T},
  title = {Factors associated with primary rifampicin-resistant/multidrug-resistant TB: a case-control study},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2026},
  doi = {10.5588/ijtld.26.0038}
}
Kostenlos starten →